title: Improvement of human islet cryopreservation by a p38 MAPK inhibitor.
abstract: The activation of p38 mitogen-activated protein kinase (MAPK) has been shown to cause ischemia/reperfusion injury of several organs used for transplantation and also to play a significant role in primary islet graft nonfunction. Activation of p38 MAPK may also occur during islet cryopreservation and thawing. In this study, a p38 MAPK inhibitor (p38IH) was applied to human islet cryopreservation to improve islet yield and quality after thawing. Under serum-free conditions, human islets were cryopreserved, thawed and cultured using our standard procedures. Three types of solutions were tested: conventional RPMI1640 medium (RPMI), a newly developed islet cryopreservation solution (ICS), and ICS supplemented with a p38IH, SD-282 (ICS-p38IH). Activation or inhibition of p38 MAPK was demonstrated by the diminished phosphorylation of HSP27 substrate. Islet recovery on day 2 after thawing was highest with ICS-p38IH and islet viability was not significantly different in the three groups. beta Cell numbers and function were the highest in islets cryopreserved with ICS-p38IH. Glucose-stimulated human C-peptide levels were 86% of that of the nonfrozen islets when measured 4 weeks after transplantation into NODscid mice. This improvement may provide an opportunity to establish islet banks and allow the use of cryopreserved islets for clinical transplantation.
authors.affiliation: Southern California Islet Cell Resources Center, Department of Diabetes, Endocrinology and Metabolism, City of Hope National Medical Center/Beckman Research Institute, Duarte, CA, USA. komori@coh.org
authors.forename: K
authors.initials: K
authors.lastname: Omori
authors.forename: L
authors.initials: L
authors.lastname: Valiente
authors.forename: C
authors.initials: C
authors.lastname: Orr
authors.forename: J
authors.initials: J
authors.lastname: Rawson
authors.forename: K
authors.initials: K
authors.lastname: Ferreri
authors.forename: I
authors.initials: I
authors.lastname: Todorov
authors.forename: I H
authors.initials: IH
authors.lastname: Al-Abdullah
authors.forename: S
authors.initials: S
authors.lastname: Medicherla
authors.forename: A A
authors.initials: AA
authors.lastname: Potter
authors.forename: G F
authors.initials: GF
authors.lastname: Schreiner
authors.forename: F
authors.initials: F
authors.lastname: Kandeel
authors.forename: Y
authors.initials: Y
authors.lastname: Mullen
mesh_terms: D000818:Animals; D002096:C-Peptide / Q000378:metabolism; D002452:Cell Count; D002470:Cell Survival; D002478:Cells, Cultured; D015925:Cryopreservation / Q000379:methods*; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism / Q000601:surgery; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005947:Glucose / Q000494:pharmacology; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D007328:Insulin / Q000378:metabolism; D007515:Islets of Langerhans / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D016381:Islets of Langerhans Transplantation / Q000379:methods; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D009926:Organ Preservation / Q000379:methods*; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D002096:C-Peptide; D004791:Enzyme Inhibitors; D007211:Indoles; D007328:Insulin; C514526:indole-5-carboxamide; D048051:p38 Mitogen-Activated Protein Kinases; D005947:Glucose